Identification of new therapeutic targets for prevention of CNS inflammation

Bibliography

• TRAPP BD, PETERSON J, RANSOHOFF RM et al: Axonal transection in the lesions of multiple sclerosis. N Engl. I Med. (1998) 338(5):278–285.
   PubMed Web of Science ®Google Scholar
• LUCCHINETTI C, BRUCK W, PARISI J et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neural. (2000) 47(6):707–717.
   PubMed Web of Science ®Google Scholar
• •References [1,2] present the 'modem' view of MS pathology viz, that it is a heterogeneous complex of pathologies [2], and that axonal loss is a common feature [1].
   Google Scholar
• PRINEAS JW, WRIGHT RG: Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest. (1978) 38(4):409–421.
   PubMed Web of Science ®Google Scholar
• TRAUGOTT U, REINHERZ EL, RAINE CS: Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science (1983) 219(4582):308–310.
   PubMed Web of Science ®Google Scholar
• MATTHEWS PM, ARNOLD DL: Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution. Cun: Opiri. Neural (2001) 14(3):279–287.
   PubMed Web of Science ®Google Scholar
• NARAYANAN S, FU L, PIORO E et al: Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann. Neural (1997) 41(3):385–391.
   PubMed Web of Science ®Google Scholar
• ARNASON BG: Immunologic therapy of multiple sclerosis. Ann. Rev. Med. (1999) 50:291–302.
   PubMed Web of Science ®Google Scholar
• •A very cogent review of approved immunotherapies for MS.
   Google Scholar
• DE STEFANO N, NARAYANAN S, FRANCIS GS et al.: Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch. Neural (2001) 58(1):65–70.
   PubMedGoogle Scholar
• ••Axonal damage occurs early in MS, and isnot simply a consequence of chronic attack over long periods of time.
   Google Scholar
• BJARTMAR C, KIDD G, MORK S, RUDICK R, TRAPP BD: Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neural (2000) 48(6):893–901.
   PubMed Web of Science ®Google Scholar
• PIKE GB, DE STEFANO N, NARAYANAN S et al.: Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology (2000) 215(3):824–830.
   PubMed Web of Science ®Google Scholar
• •Shows that white matter abnormality precedes overt inflammation.
   Google Scholar
• GOODIN DS, FROHMAN EM, GARMANY, GP JR etal.: Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology (2002) 58(2):169–178.
   Google Scholar
• YONG VW, KREKOSKI CA, FORSYTH PA, BELL R, EDWARDS DR: Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. (1998) 21(2):75–80.
   PubMed Web of Science ®Google Scholar
• YONG VW, POWER C, FORSYTH P, EDWARDS DR: Metalloproteinases in biology and pathology of the nervous system. Nat. Rev Neurosci. (2001) 2(7):502–511.
   PubMed Web of Science ®Google Scholar
• •A timely review on the MMPs and their relatives.
   Google Scholar
• VANDENBARK AA, HASHIM G, OFFNER H: Immunization with a synthetic T cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature (1989) 341(6242):541–544.
   PubMed Web of Science ®Google Scholar
• ZANG YC, HONG J, RIVERA VM, KILLIAN J, ZHANG JZ: Preferential recognition of TCR hypervariable regions by human anti- idiotypic T cells induced by T cell vaccination. j Immune]. (2000) 164(8):4011–4017.
   PubMed Web of Science ®Google Scholar
• MEDAER R, STINISSEN P, TRUYEN L, RAUS J, ZHANG J: Depletion of myelin-basic-protein autoreactive T cells by T cell vaccination: pilot trial in multiple sclerosis. Lancet (1995) 346(8978):807–808.
   PubMed Web of Science ®Google Scholar
• CALABRESI PA, WILTERDINK JL, ROGG JM et al: An open-label trial of combination therapy with interferon beta-la and oral methotrexate in MS. Neurology (2002) 58(2):314–317.
   PubMed Web of Science ®Google Scholar
• OWENS T, MURPHY T, MINTON K: Vhh International Congress of Neuroimmunology. Edinburgh, Scotland, September 3–7, 2001.1 Neuraimmurial. (2002) (In Press).
   Google Scholar
• RODRIGUEZ M, MILLER DJ, LENNON VA: Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology (1996) 46(2):538–545.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ M, MOALEM G, LEIBOWITZ-AMIT R, COHEN IR: Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci. (1999) 22(7):295–299.
   PubMed Web of Science ®Google Scholar
• ••References [19,20] make the case forbeneficial effects of immune responses in the CNS.
   Google Scholar
• DEBOVE C, ZEISSER P, SALZMAN PM, POWE LK, TRUFFINET P: The Rilutek (riluzole) global early access programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis. Antyatraph. Lateral Scler. Other Motor Neuron Disord. (2001) 2(3):153–158.
   PubMed Web of Science ®Google Scholar
• BIELEKOVA B, GOODWIN B, RICHERT N et al.: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nat. Med. (2000) 6(10):1167–1175.
   PubMed Web of Science ®Google Scholar
• KAPPOS L, COMI G, PANITCH H et al: Induction of a non-encephalitogenic Type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized Phase II trial. Nat. Med. (2000) 6(10):1176–1182.
   PubMed Web of Science ®Google Scholar
• GENAIN CP, CANNELLA B, HAUSER SL, RAINE CS: Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. (1999) 5(2):170–175.
   PubMed Web of Science ®Google Scholar
• •This paper showed the deleterious effect of Thl->Th2 switch in EAE in marmosets. Antibody responses were enhanced and animals died.
   Google Scholar
• GEORGE A, MARZINIAK M, SCHAFERS M, TOYKA KV, SOMMER C: Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain (2000) 88(3):267–275.
   PubMed Web of Science ®Google Scholar
• MARRIOTT JB, MULLER G, DALGLEISH AG: Thalidomide as an emerging immunotherapeutic agent. Immune]. Today (1999) 20(12):538–540.
   PubMedGoogle Scholar
• SASTRY PS: Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis. Med. Hypotheses (1999) 53(1):76–77.
   PubMed Web of Science ®Google Scholar
• TSENOVA L, BERGTOLD A, FREEDMAN VH, YOUNG RA, KAPLAN G: Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc. Natl. Acad. Sci. USA (1999) 96(10):5657–5662.
   PubMed Web of Science ®Google Scholar
• SZABO SJ, DIGHE AS, GUBLER U, MURPHY KM: Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Thl) and Th2 cells. j. Exp. Med. (1997) 185(5):817–824.
   PubMed Web of Science ®Google Scholar
• BECHER B, GIACOMINI PS, PELLETIER D et al.: Interferon-gamma secretion by peripheral blood T cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann. Neural (1999) 45(2):247–250.
   PubMed Web of Science ®Google Scholar
• OWENS T, WEKERLE H, ANTEL J: Genetic models for CNS inflammation. Nat. Med. (2001) 7(2):161–166.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of transgenic and knockout models of immune mediators in EAE.
   Google Scholar
• PANITCH HS, HIRSCH RL, HALEY AS, JOHNSON KP: Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet (1987) 1(8538):893–895.
   PubMed Web of Science ®Google Scholar
• ••Probably the only clinical trial that willever be carried out of IFNI in MS.
   Google Scholar
• BEVER CT JR, PANITCH HS, LEVY HB, MCFARLIN DE, JOHNSON KP: Gamma-interferon induction in patients with chronic progressive MS. Neurology (1991) 41(7):1124–1127.
   PubMed Web of Science ®Google Scholar
• BILLIAU A, HEREMANS H, VANDEKERCKHOVE F et al: Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. j bronurial (1988) 140(5):1506–1510.
   Google Scholar
• VOORTHUIS JA, UITDEHAAG BM, DE GROOT CJ etal.: Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats. an. Exp. konurial (1990) 81(2):183–188.
   Google Scholar
• SETHNA ME LAMPSON LA: Immune modulation within the brain: recruitment of inflammatory cells and increased major histocompatibility antigen expression following intracerebral injection of interferon-gamma. j. Neurainunurral (1991) 34(2-3):121–132.
   Google Scholar
• SIMMONS RD, WILLENBORG DO: Direct injection of cytokines into the spinal cord causes autoimmune encephalomyelitis-like inflammation. j. Neural Li (1990) 100(1-2):37–42.
   Google Scholar
• FURLAN R, BRAMBILLA E, RUFFINI F et al.: Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. j. hinnurial (2001) 167(3):1821–1829.
   Google Scholar
• KRAKOWSKI M, OWENS T: Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur. I hinnurial (1996) 26(7):1641–1646.
   PubMed Web of Science ®Google Scholar
• TRAN EH, PRINCE EN, OWENS T: IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. j Inunurral (2000) 164(5):2759–2768.
   Google Scholar
• •This paper provides a mechanistic explanation why IFNI/ blockade might worsen EAE.
   Google Scholar
• PITT D, WERNER P, RAINE CS: Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. (2000) 6(1):67–70.
   PubMed Web of Science ®Google Scholar
• ••Shows that the excitotoicin glutamatemediates axonal damage in EAE, and that this is critical for disease.
   Google Scholar
• GAO X, GILLIG TA, YE P et al: Interferon-gamma protects against cuprizone-induced demyelination. Mal. Cell. Neurosci. (2000) 16(4):338–349.
   PubMed Web of Science ®Google Scholar
• NEUMANN H, SCHMIDT H, WILHARM E, BEHRENS L, WEKERLE H: Interferon gamma gene expression in sensory neurons: evidence for autocrine gene regulation. I Exp. Med. (1997) 186(12):2023–2031.
   PubMed Web of Science ®Google Scholar
• FRUCHT DM, FUKAO T, BOGDAN C et al.: IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends hinnurial (2001) 22(10):556–560.
   Google Scholar
• DE SIMONE R, LEVI G, ALOISI F: Interferon gamma gene expression in rat central nervous system glial cells. Cytakine (1998) 10(6):418–422.
   Google Scholar
• HUSEBY ES, LIGGITT D, BRABB T et al.: A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. j. Exp. Med. (2001) 194(5):669–676.
   PubMed Web of Science ®Google Scholar
• ••One of the first two papers to show thatCD8+ T cells can induce EAE. This paper also showed that IFN-y blockade alleviated EAE.
   Google Scholar
• CHU CQ, WITTIVIER S, DALTON DK: Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. I Exp. Med. (2000) 192(1):123–128.
   PubMed Web of Science ®Google Scholar
• WILLENBORG DO, FORDHAM SA, STAYKOVA MA, RAMSHAW IA, COWDEN WB: IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. j. Inunurral (1999) 163(10):5278–5286.
   Google Scholar
• WILLENBORG DO, STAYKOVA MA, COWDEN WB: Our shifting understanding of the role of nitric oxide in autoimmune encephalomyelitis: a review. Neurainnnurial (1999) 100(1–2):21-35. A comprehensive and critical review of the role of nitric oxide in MS and EAE.
   Google Scholar
• FENYK-MELODY JE, GARRISON AE, BRUNNERT SR et al.: Experimental autoimmune encephalomyelitis is exacerbated in mice lacking the N052 gene. ?Inunurral (1998) 160(6):2940–2946.
   Google Scholar
• SAHRBACHER UC, LECHNER F, EUGSTER HP et al.: Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis. Eur. j Immunol (1998) 28(4):1332–1338.
   PubMed Web of Science ®Google Scholar
• GREGERSEN R, LAMBERTSEN K, FINSEN B: Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. j Cereb. Blood Flow Metab. (2000) 20(1):53–65.
   PubMed Web of Science ®Google Scholar
• RENNO T, KRAKOWSKI M, PICCIRILLO C, LIN JY, OWENS T: TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Thl cytokines. I Immune]. (1995) 154(2):944–953.
   Google Scholar
• ••This paper demonstrates that bothmacrophages and resident microglial cells are major sources of the inflammatory cytokine TNF in EAE.
   Google Scholar
• SELMAJ KW, RAINE CS: Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neural (1988) 23(4):339–346.
   PubMed Web of Science ®Google Scholar
• ••This paper showed the potential for TNF tokill oligodendrocytes, a finding that spurred a generation of research on TNF in MS.
   Google Scholar
• SELMAJ K, RAINE CS, CROSS AH: Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neural (1991) 30(5):694–700.
   PubMed Web of Science ®Google Scholar
• SOMMER N, LOSCHMANN PA, NORTHOFF GH et al.: The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis [see comments]. Nat. Med. (1995) 1(3):244–248.
   PubMed Web of Science ®Google Scholar
• EUGSTER HE FRET K, BACHMANN R et al: Severity of symptoms and demyelination in MOG-induced EAE depends on TNER1. Eur. j Immune]. (1999) 29(2):626–632.
   PubMed Web of Science ®Google Scholar
• PROBERT L, AKASSOGLOU K, KASSIOTIS G et al: TNF-alpha transgenic and knockout models of CNS inflammation and degeneration. I Neuraimmurial. (1997) 72(2):137–141.
   PubMed Web of Science ®Google Scholar
• AKASSOGLOU K, PROBERT L, KONTOGEORGOS G, KOLLIAS G: Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. I 'minimal. (1997) 158(1):438–445.
   Google Scholar
• RUULS SR, HOEK RIVI, NGO VN et al: Membrane-bound tnf supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity (2001) 15(4)533–543.
   Google Scholar
• ••An important paper, which shows thatmembrane-bound TNF is not very important for inflammation, but is critical for lymphoid development.
   Google Scholar
• KORNER H, RIMINTON DS, STRICKLAND DH et al.: Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. I Exp. Med. (1997) 186(9):1585–1590.
   PubMed Web of Science ®Google Scholar
• •Shows that TNF is not necessary for EAE, but plays a critical role in promoting leukocyte entry to the CNS.
   Google Scholar
• LIU J, MARINO MW, WONG G et al: TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. (1998) 4(1):78–83.
   PubMed Web of Science ®Google Scholar
• KASSIOTIS G, KOLLIAS G: Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level. Implications for pathogenesis and therapy of autoimmune demyelination. Exp. Med. (2001) 193(4):427–434.
   Google Scholar
• PFEFFER K, MATSUYAMA T, KUNDIG TM et al.: Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to Lmoriacytageries infection. Cell (1993) 73(3):457–467.
   PubMed Web of Science ®Google Scholar
• BRUCE AJ, BOLING W, KINDY MS et al.: Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. (1996) 2(7):788–794.
   PubMed Web of Science ®Google Scholar
• ••This paper revealed a neuroprotective roleof TNF in the CNS.
   Google Scholar
• ARNETT HA, MASON J, MARINO M et al.: TNFalpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. (2001) 4(11):1116–1122.
   PubMed Web of Science ®Google Scholar
• ••Shows a potentially protective role for TNF in the CNS, at the level of oligodendrocyte growth promotion.
   Google Scholar
• JENSEN MB, HEGELUND IV, LOMHOLT ND, FINSEN B, OWENS T: IFN-gamma enhances microglial reactions to hippocampal axonal degeneration. Neurosci. (2000) 20(10):3612–3621.
   Web of Science ®Google Scholar
• •This paper shows interplay between the adaptive immune response mediator IFNI and the innate CNS glial response to injury.
   Google Scholar
• HUANG DW, MCKERRACHER L, BRAUN PE, DAVID S: A therapeutic vaccine approach to stimulate axon regeneration in the adult mammalian spinal cord. Neuron (1999) 24(3):639–647.
   PubMed Web of Science ®Google Scholar
• GODDARD DR, BUNNING RA, WOODROOFE MN: Astrocyte and endothelial cell expression of ADAM 17 (TACE) in adult human CNS. Clia (2001) 34(4):267–271.
   Google Scholar
• FELDMANN M, MAINI RN: Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Ann. Rev Immune]. (2001) 19:163–196.
   PubMed Web of Science ®Google Scholar
• •Reviews the beneficial effects of TNF blockade in arthritis.
   Google Scholar
• WIENDL H, NEUHAUS O, KAPPOS L, HOHLFELD R: Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment. Nerveriarzt (2000) 71(8):597–610.
   Google Scholar
• THE LENERCEPT MULTIPLE SCLEROSIS STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology (1999) 53(3):457–465.
   PubMed Web of Science ®Google Scholar
• •A report on the clinical trial in which TNF blockade was shown to not alleviate MS.
   Google Scholar
• HICKEY WF, VASS K, LASSMANN H: Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras. I Neurapathol. Esp. Neural. (1992) 51(3):246–256.
   PubMed Web of Science ®Google Scholar
• LAWSON LJ, PERRY VH, GORDON S: Turnover of resident microglia in the normal adult mouse brain. Neuroscience (1992) 48(2):405–415.
   PubMed Web of Science ®Google Scholar
• HOEK RIVI, RUULS SR, MURPHY CA et al.: Down-regulation of the macrophage lineage through interaction with 0X2 (CD200). Science (2000) 290(5497):1768–1771.
   PubMed Web of Science ®Google Scholar
• ONO K, TAKII T, ONOZAKI K et al.: Migration of exogenous immature hematopoietic cells into adult mouse brain parenchyma under GFP-expressing bone marrow chimera. Biachem. Biaphys. Res. Commun. (1999) 262(3):610–614.
   PubMed Web of Science ®Google Scholar
• SRIRAM S, RODRIGUEZ M: Indictment of the microglia as the villain in multiple sclerosis. Neurology (1997) 48(2):464–470.
   PubMed Web of Science ®Google Scholar
• MENNICKEN F, MAKI R, DE SOUZA EB, QUIRION R: Chemokines and chemokine receptors in the CNS: a possible role in
   Google Scholar